Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-Onset Systemic Lupus Erythematosus

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 4, 2011, Pages 307-313

  Sagcal Gironella, Anna Carmela P ^a   Fukuda, Tsuyoshi ^a,c   Wiers, Kristina ^a   Cox, Shareen ^a   Nelson, Shannen ^a   Dina, Blair ^b   Sherwin, Catherine M T ^a   Klein Gitelman, Marisa S ^b   Vinks, Alexander A ^a,c   Brunner, Hermine I ^a,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Inosine 5' monophosphate dehydrogenase (IMPDH); Mycophenolic acid; Pharmacodynamics; Pharmacokinetics; Systemic lupus erythematosus

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYCHLOROQUINE; INOSINATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; ONSET AGE; PHARMACODYNAMICS; PRESCHOOL CHILD; PRIORITY JOURNAL; RELIABILITY; SCHOOL CHILD; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MYCOPHENOLIC ACID;

EID: 78751702920     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.05.007     Document Type: Article

References (47)

1. Morris R.E., Hoyt E.G., Murphy M.P., Eugui E.M., Allison A.C. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990, 22(4):1659-1662.
2. Allison A.C., Eugui E.M. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47(2-3):85-118.
3. Allison A.C., Eugui E.M. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc 1994, 26(6):3205-3210.
4. Ransom J.T. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995, 17(6):681-684.
5. Chaigne-Delalande B., Guidicelli G., Couzi L., Merville P., Mahfouf W., Bouchet S., et al. The immunosuppressor mycophenolic acid kills activated lymphocytes by inducing a nonclassical actin-dependent necrotic signal. J Immunol 2008, 181(11):7630-7638.
6. Alba P., Karim M.Y., Hunt B.J. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003, 12(8):633-635.
7. Vasoo S., Thumboo J., Fong K.Y. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003, 12(8):630-632.
8. Schanz S., Ulmer A., Rassner G., Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002, 147(1):174-178.
9. Gaubitz M., Schorat A., Schotte H., Kern P., Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999, 8(9):731-736.
10. Falcini F., Capannini C., Martini M., La Torre L., Vitale V., Nacci N., et al. Mycophenolate mofetil (MMF) for the treatment of juvenile onset systemic lupus erythematosus. Pediatr Rheumatol 2008, 6(Suppl 1):P234.
11. Tannuri U., Gibelli N.E., Maksoud-Filho J.G., Santos M.M., Pinho-Apezzato M.L., Velhote M.C., et al. Mycophenolate mofetil promotes prolonged improvement of renal dysfunction after pediatric liver transplantation: experience of a single center. Pediatr Transplant 2007, 11(1):82-86.
12. Jungraithmayr T.C., Wiesmayr S., Staskewitz A., Kirste G., Bulla M., Fehrenbach H., et al. Five-year outcome in pediatric patients with mycophenolate mofetil-based renal transplantation. Transplantation 2007, 83(7):900-905.
13. Cransberg K., Cornelissen M., Lilien M., Van Hoeck K., Davin J.C., Nauta J. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk. Transplantation 2007, 83(8):1041-1047.
14. Ojogho O., Sahney S., Cutler D., Baron P.W., Abdelhalim F.M., James S., et al. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab. Pediatr Transplant 2005, 9(1):80-83.
15. Lobritto S.J., Rosenthal P., Bouw R., Leung M., Snell P., Mamelok R.D. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. Liver Transpl 2007, 13(11):1570-1575.
16. Ettenger R., Cohen A., Nast C., Moulton L., Marik J., Gales B. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation. Transplant Proc 1997, 29(1-2):340-341.
17. Hocker B., Weber L.T., Bunchman T., Rashford M., Tonshoff B. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial. Pediatr Transplant 2005, 9(4):504-511.
18. Cattaneo D., Perico N., Gaspari F., Gotti E., Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002, 62(3):1060-1067.
19. Sherwin C., Fukuda T., Goebel J., Brunner H.I., Vinks A.A. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet 2009, (in press).
20. Le Meur Y., Buchler M., Thierry A., Caillard S., Villemain F., Lavaud S., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007, 7(11):2496-2503.
21. Jeong H., Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2007, 2(1):184-191.
22. Lu Y.P., Zhu Y.C., Liang M.Z., Nan F., Yu Q., Wang L., et al. Therapeutic drug monitoring of mycophenolic acid can be used as predictor of clinical events for kidney transplant recipients treated with mycophenolate mofetil. Transplant Proc 2006, 38(7):2048-2050.
23. Glander P., Hambach P., Braun K.P., Fritsche L., Waiser J., Mai I., et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003, 41(10):470-476.
24. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46(1):13-58.
25. Weimert N.A., Derotte M., Alloway R.R., Woodle E.S., Vinks A.A. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications. Ther Drug Monit 2007, 29(2):141-149.
26. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
27. Hay E.M., Bacon P.A., Gordon C., Isenberg D.A., Maddison P., Snaith M.L., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86(7):447-458.
28. Yee C.S., Isenberg D.A., Prabu A., Sokoll K., Teh L.S., Rahman A., et al. BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000. Ann Rheum Dis 2008, 67(6):873-876.
29. Cellcept [Package Insert] 2009, Roche Laboratories, Inc, Nutley, NJ, USA.
30. Glander P., Braun K.P., Hambach P., Bauer S., Mai I., Roots I., et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001, 34(7):543-549.
31. Glander P., Sombogaard F., Budde K., van Gelder T., Hambach P., Liefeldt L., et al. Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells. Ther Drug Monit 2009, 31(3):351-359.
32. Zahr N., Amoura Z., Debord J., Hulot J.S., Saint-Marcoux F., Marquet P., et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 2008, 47(4):277-284.
33. Roland M., Barbet C., Paintaud G., Magdelaine-Beuzelin C., Diot E., Halimi J.M., et al. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus 2009, 18(5):441-447.
34. Kuypers D.R., de Jonge H., Naesens M., de Loor H., Halewijck E., Dekens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008, 30(4):673-683.
35. Franzblau A.N. A primer of statistics for non-statisticians 1958, Harcourt, New York (NY).
36. Brunner H.I., Higgins G.C., Wiers K., Lapidus S.K., Olson J.C., Onel K., et al. Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. J Rheumatol 2009, 36(7):1536-1545.
37. Wais T., Fierz W., Stoll T., Villiger P.M. Subclinical disease activity in systemic lupus erythematosus: immunoinflammatory markers do not normalize in clinical remission. J Rheumatol 2003, 30(10):2133-2139.
38. van Hest R.M. Population-specific limited sampling strategies for therapeutic drug monitoring of mycophenolic acid. J Postgrad Med 2006, 52(4):244.
39. Armstrong V.W., Shipkova M., Schutz E., Weber L., Tonshoff B., Oellerich M. Monitoring of mycophenolic acid in pediatric renal transplant recipients. Transplant Proc 2001, 33(1-2):1040-1043.
40. Zahr N., Hulot J., Haroche J., Debord J., Costedoat-Chalumeau N., Cacoub P., et al. Low mycophenolic acid area under the curve is associated with increased systemic lupus erythematosus activity [Abstract]. Fundam Clin Pharmacol 2008, 22(s1):23.
41. Arnaud L., Zahr N., Haroche J., Hulot J., Marquet P., Funck-Brentano C., et al. Low mycophenolic acid area under the curve Is a major parameter of systemic lupus erythematosus activity [Abstract]. Arthritis Rheum 2009, 60(s1).
42. Soars M.G., Petullo D.M., Eckstein J.A., Kasper S.C., Wrighton S.A. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004, 32(1):140-148.
43. Kanou M., Usui T., Ueyama H., Sato H., Ohkubo I., Mizutani T. Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Mol Biol Rep 2004, 31(3):151-158.
44. Djebli N., Picard N., Rerolle J.P., Le Meur Y., Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genom 2007, 17(5):321-330.
45. Lam S., Partovi N., Ting L.S., Ensom M.H. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother 2008, 42(7):1037-1047.
46. Kuypers D.R., Claes K., Evenepoel P., Maes B., Coosemans W., Pirenne J., et al. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients. J Clin Pharmacol 2003, 43(8):866-880.
47. Gregoor P.J., de Sevaux R.G., Hene R.J., Hesse C.J., Hilbrands L.B., Vos P., et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999, 68(10):1603-1606.